Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth S Kleffel, C Posch, SR Barthel, H Mueller, C Schlapbach, E Guenova, ... Cell 162 (6), 1242-1256, 2015 | 658 | 2015 |
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo C Posch, H Moslehi, L Feeney, GA Green, A Ebaee, V Feichtenschlager, ... Proceedings of the National Academy of Sciences 110 (10), 4015-4020, 2013 | 246 | 2013 |
The risk of melanoma in airline pilots and cabin crew: a meta-analysis M Sanlorenzo, MR Wehner, E Linos, J Kornak, W Kainz, C Posch, I Vujic, ... JAMA dermatology 151 (1), 51-58, 2015 | 127 | 2015 |
Melanoma immunotherapy M Sanlorenzo, I Vujic, C Posch, A Dajee, A Yen, S Kim, M Ashworth, ... Cancer biology & therapy 15 (6), 665-674, 2014 | 99 | 2014 |
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma M Sanlorenzo, A Choudhry, I Vujic, C Posch, K Chong, K Johnston, ... Journal of the American Academy of Dermatology 71 (6), 1102-1109. e1, 2014 | 91 | 2014 |
DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics A Latorre, C Posch, Y Garcimartín, A Celli, M Sanlorenzo, I Vujic, J Ma, ... Nanoscale 6 (13), 7436-7442, 2014 | 78 | 2014 |
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer I Vujic, M Sanlorenzo, C Posch, R Esteve-Puig, AJ Yen, A Kwong, ... Oncotarget 6 (2), 969, 2015 | 75 | 2015 |
Mycoplasma pneumoniae‐associated mucositis – case report and systematic review of literature I Vujic, A Shroff, M Grzelka, C Posch, B Monshi, M Sanlorenzo, ... Journal of the European Academy of Dermatology and Venereology 29 (3), 595-598, 2015 | 70 | 2015 |
The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients C Posch, B Monshi, T Quint, I Vujic, N Lilgenau, K Rappersberger Journal Of The American Academy Of Dermatology 77 (1), 123-129. e5, 2017 | 69 | 2017 |
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients T Amaral, F Kiecker, S Schaefer, H Stege, K Kaehler, P Terheyden, ... Journal for immunotherapy of cancer 8 (1), 2020 | 65 | 2020 |
Apremilast in psoriasis–a prospective real‐world study I Vujic, R Herman, M Sanlorenzo, C Posch, B Monshi, K Rappersberger, ... Journal of the European Academy of Dermatology and Venereology 32 (2), 254-259, 2018 | 64 | 2018 |
Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma C Posch, BD Cholewa, I Vujic, M Sanlorenzo, J Ma, ST Kim, S Kleffel, ... Journal of Investigative Dermatology 135 (10), 2475-2483, 2015 | 61 | 2015 |
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for ImmunoTherapy of Cancer 9 (1), 2021 | 60 | 2021 |
Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients B Monshi, C Posch, I Vujic, A Sesti, S Sobotka, K Rappersberger Journal of the American Academy of Dermatology 71 (4), 738-744, 2014 | 58 | 2014 |
The burden of malignant melanoma–lessons to be learned from Austria B Monshi, M Vujic, D Kivaranovic, A Sesti, W Oberaigner, I Vujic, ... European journal of cancer 56, 45-53, 2016 | 45 | 2016 |
A prospective study of mobile phones for dermatology in a clinical setting J Weingast, C Scheibböck, EMT Wurm, E Ranharter, S Porkert, S Dreiseitl, ... Journal of telemedicine and telecare 19 (4), 213-218, 2013 | 45 | 2013 |
The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes M Sanlorenzo, I Vujic, C Posch, JE Cleaver, P Quaglino, S Ortiz-Urda JAMA dermatology 151 (4), 450-452, 2015 | 42 | 2015 |
Phosphoproteomic analyses of NRAS (G12) and NRAS (Q61) mutant melanocytes reveal increased CK2α kinase levels in NRAS (Q61) mutant cells C Posch, M Sanlorenzo, I Vujic, JA Oses-Prieto, BD Cholewa, ST Kim, ... Journal of Investigative Dermatology 136 (10), 2041-2048, 2016 | 37 | 2016 |
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells I Vujic, M Sanlorenzo, R Esteve-Puig, M Vujic, A Kwong, A Tsumura, ... Oncotarget 7 (6), 7297, 2016 | 37 | 2016 |
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients C Posch, F Weihsengruber, K Bartsch, V Feichtenschlager, M Sanlorenzo, ... British journal of cancer 110 (6), 1427-1432, 2014 | 35 | 2014 |